louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04074369: Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects
Official title: Evaluation of CRISPR-based Test for the Rapid Identification of Mycobacterium Tuberculosis Complex in Pulmonary Tuberculosis Suspects
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tuberculosis, Pulmonary
Lead sponsor: Huashan Hospital
Sponsor class: OTHER
Collaborators: name: Wenzhou Central Hospital
name: Red Cross Hospital, Hangzhou, China
First posted: 2019-08-30
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Suspected pulmonary TB patients in Huashan Hospital, Wenzhou Central Hospital and Hangzhou Red Cross Hospital.

Brief summary: This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a prospective study of pulmonary TB suspects who are undergoing sputum or bronchoalveolar lavage fluid (BALF) evaluation for pulmonary TB. The sensitivity and specificity of the CRISPR-based assay will be compared to clinical diagnosis, conventional culture methods and Xpert MTB/RIF assay on same batch specimens.


Eligibility criteria: Inclusion Criteria:

* Suspected pulmonary TB.
* Ability and willingness of candidate or legal guardian/representative to provide informed consent.
* Men and women age equal to or greater than 18 years.

Exclusion Criteria:

* Either receipt of ≥48 cumulative hours OR three or more doses of anti-TB treatment within 180 days prior to completion of second sputum collection for Xpert testing

Primary outcomes:
measure: Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay positive and/or MGIT culture positive for M.tuberculosis.
timeFrame: week 0
measure: Proportion of clinically diagnosed TB participants with CRISPR-based test MTB positive in sputum/BALF who are Xpert MTB/RIF Assay negative and/or MGIT culture negative for M.tuberculosis.
timeFrame: week 0
measure: Proportion of clinically diagnosed non-TB participants with CRISPR-based test MTB positive in sputum/BALF.
timeFrame: week 0
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Huashan Hospital
state: Shanghai
Study officials:
References:
citation: Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, Ochodo EA, Haraka F, Zwerling AA, Pai M, Steingart KR, Horne DJ. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD009593. doi: 10.1002/14651858.CD009593.pub5.
Clinical trial NCT06085469: Investigation of the Effects of Temporal Adaptation Approach in Post-Discharge Stroke Individuals
Official title: Investigation of the Effects of Temporal Adaptation Approach in Post-Discharge Stroke Individuals: A Randomized Controlled Study With One Month Follow-up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Keywords: Rehabilitation, human activities, participation
Lead sponsor: Kutahya Health Sciences University
Sponsor class: OTHER
First posted: 2023-10-17
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Abstract Introduction: Stroke is a disease that makes it difficult to participate in daily life activities by creating functional losses. Healthy temporal adaptation can increase and support engagement in meaningful activities. This study aims to analyze the effect of the temporal adaptation approach on the post-discharge occupational engagement of individuals with stroke.

Methods: This study is a randomized controlled trial with 1 month follow-up. While the TAA approach was applied to the first group, the general condition of the second group was followed during the study. Canadian Occupational Performance Measue was administered to assess occupational performance and satisfaction, and Occupational Balance Questionnaire was for occupational balance.

Kewords: Time, stroke, rehabilitation, human activities, participation


Eligibility criteria: Inclusion Criteria:

* The inclusion criteria used for this study are as follows: being in the chronic phase of the stroke disease (˃6 months) and score of ˃26 on the Montreal Cognitive Assessment (MoCA).

Exclusion Criteria:

* Exclusion criteria used are as follows: diagnosis of a psychiatric illness strongly affects the participation to daily life activities according to medical reports (such as schizophrenia or bipolar disorder), a physical condition other than stroke that requires medical follow-up (fracture, osteoporosis, etc.) and aphasia that would affect the intervention via interview

Primary outcomes:
measure: Canadian Occupational Performance Measure
timeFrame: 30 minutes
measure: Occupational Balance Questionnaire
timeFrame: 10 minutes
Secondary outcomes:
measure: Modified Occupational Questionnaire
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Kütahya
country: Turkey
facility: Kutahya Health Sciences University
Study officials:
affiliation: Kutahya Health Sciences University
name: İbrahim Y. TATLI, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01570569: Development of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human
Official title: Development of High-throughput Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Volunteers
Lead sponsor: Inje University
Sponsor class: OTHER
First posted: 2012-04-04
Enrollment: 26
Sex: MALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators objectives were developing mini dose five-drug cocktail regimen to evaluate potential drug-drug interactions associated with use of a cocktail of caffeine, losartan, omeprazole, dextromethorphan, and midazolam for simultaneous assessment of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A activities.

Detailed description: The investigators objectives were developing minidose five-drug cocktail regimen to evaluate potential drug-drug interactions associated with use of a cocktail of caffeine, losartan, omeprazole, dextromethorphan, and midazolam for simultaneous assessment of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A activities.

Eligibility criteria: Inclusion Criteria:

* Healthy male subject whose CYP2C9, CYP2C19, CYP2D6 genotype was determined

Exclusion Criteria:

* Subject who has abnormal laboratory test results

Primary outcomes:
measure: Cmax, AUC
timeFrame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Inje University
name: Jae Gook Shin, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03767569: Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients
Official title: Pretreatment With Myo-inositol in Hyperandrogenic PCOS Patients Undergoing ART: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: PCOS
Female Infertility
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2018-12-06
Enrollment: 134
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled trial
Primary purpose: TREATMENT

Brief summary: A randomized controlled trial to evaluate whether pretreatment with myo-inositol can lower testosterone levels and improve clinical outcomes in hyperandrogenic PCOS patients undergoing ART


Eligibility criteria: Inclusion Criteria:

* Women aged 18-40 years
* PCOS phenotypes A, B and C
* Signed informed consent

Exclusion Criteria:

* Other relevant endocrine disorders
* Contraindications to the use of gonadotropins
* Endometriosis grade 3-4
* BMI \> 35

Primary outcomes:
measure: Serum testosterone level after 12 weeks of administration of Myo-Inositol
timeFrame: 2 years
Secondary outcomes:
measure: Androstenedione and SHBG (Sex Hormone Binding Globulin) plasma levels after 12 weeks of administration of Myo-Inositol
timeFrame: 2 years
measure: Number of mature oocytes
timeFrame: 2 years
measure: Embryo quality
timeFrame: 2 years
measure: Implantation rate (%)
timeFrame: 2 years
measure: Clinical pregnancy rate (%)
timeFrame: 2 years
measure: Live birth rate in fresh cycle
timeFrame: 2 years
measure: Cumulative live birth rate after 1 cycle
timeFrame: 2 years
measure: Ovarian Hyperstimulation Syndrome rate
timeFrame: 2 years
measure: Consumption of gonadotrophins
timeFrame: 2 years
measure: Stimulation days
timeFrame: 2 years
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Universitair Ziekenhuis Brussel
Study officials:
References:
Clinical trial NCT03521869: The Need for Compression Bandage Following Total Knee Arthroplasty A Prospective Randomized Controlled Trial Conducted in Simultaneous Bilateral Total Knee Replacements
Official title: The Need for Compression Bandage Following Total Knee Arthroplasty A Prospective Randomized Controlled Trial Conducted in Simultaneous Bilateral Total Knee Replacements
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteo Arthritis Knee
Lead sponsor: Rothman Institute Orthopaedics
Sponsor class: OTHER
First posted: 2018-05-11
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Only bilateral knee replacements will be utilized so each patient can serve as their internal control
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate if applying a compression bandage on the leg alters early outcome following TKA.

The primary objective of this study is to evaluate leg swelling by measuring leg circumference following simultaneous bilateral total knee arthroplasty (TKA) with and without the application of compression bandage.


Eligibility criteria: Inclusion Criteria:

* All patients receiving elective simultaneous bilateral primary total knee arthroplasty, treated by Rothman physicians at the Thomas Jefferson University Hospital or Rothman Specialty Hospital.

Exclusion Criteria:

* Previous venous thromboembolic event.
* Lymph edema in one or both legs.
* BMI \> 40
* Prior surgery (other than arthroscopy)

Primary outcomes:
measure: swelling of the knee
timeFrame: one day following surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Rothman Institute
state: Pennsylvania
Study officials:
affiliation: Rothman Institute
name: Tiffany Morrison, MS, CCRP
role: STUDY_DIRECTOR
References:
Clinical trial NCT02509169: Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
Official title: Trans-catheter Arterial p53-gene-embolization Using Gelatin Sponge Particles in Treatment of Patients With Advanced Hepatocellular Carcinoma: A Phase II Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor: Shenzhen SiBiono GeneTech Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2015-07-27
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: An open-labeled, randomized, active-controlled phase II study to investigate clinical efficacy and immunoreaction using trans-catheter arterial embolization (TAE) combined with p53 gene therapy in treatment of advanced hepatocellular carcinoma (HCC).

Detailed description: Treatment options for advanced HCC are limited due to patients' poor condition, advanced stage, concomitant intra- and extra-liver diseases, and resistance to both chemo- and radio-therapy. Trans-catheter embolization (TAE) is a safe locoregional treatment for advanced HCC and p53 gene has multiple anticancer functions, and both methods do not have immune-inhibitory effects as chemo- or radio-therapy. The objectives of this study are to investigate clinical efficacy and immunoreaction usingTAE plus recombinant adenoviral human p53 gene (rAd-p53) in treatment of advanced HCC.

Eligibility criteria: Inclusion Criteria:

* histopathologically diagnosed unresectable HCC
* over 18 years old
* with an Eastern Cooperative Oncology Group (ECOG) score of 0-2
* with Barcelona Clinic Liver Cancer (BCLC) Stage of B or C
* with Child-Pugh score A or B; with normal tests of hemogram, blood coagulation, liver and kidney function
* signed the informed consent form.

Exclusion Criteria:

* hypersensitive to study drug
* With an abnormal coagulation condition or bleeding disorder
* infections
* with serious conditions which prevent using the study treatment
* pregnant or lactating

Primary outcomes:
measure: overall survival
timeFrame: 2 years
Secondary outcomes:
measure: immuno-reaction (lymphocyte counts and subgroup ratios)
timeFrame: 3 months
measure: progression free survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Dalian
country: China
facility: first affiliated hospital in Dalian University
state: Liaoning
Study officials:
References:
Clinical trial NCT07008469: Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Official title: A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Myotonic Dystrophy Type 1
DM1
Myotonic Dystrophy
Myotonia
Myotonic Dystrophy 1
Myotonic Disorders
Steinert Myotonic Dystrophy
Steinert&#39;s Disease
Keywords: DM1
Myotonic Dystrophy
Myotonic Dystrophy 1
Myotonia
Myotonic Dystrophy Type 1 (DM1)
Dystrophy Myotonic
Myotonic Disorders
Steinert Disease
Steinert
Myotonic Muscular Dystrophy
HARBOR-OLE
Avidity Biosciences
Avidity
AOC 1001
Del-desiran
Delpacibart etedesiran
HARBOR
Lead sponsor: Avidity Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2025-06-06
Enrollment: 217
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

Detailed description: The study consists of a Screening Period of up to either 4-weeks or 8-weeks depending on the prior parent trial, and up to a 4-year Treatment Period. The anticipated duration is 50 months and 2 weeks (4 years and 2.5 months).

Participants will receive an intravenous infusion of del-desiran at the clinical study site every 8 weeks for a total of 7 doses per year. The final dose will occur at Year 4, Visit 7, followed by a final assessment 8 weeks after the last dose.

An Independent Data Monitoring Committee (IDMC) comprised of members independent and external to the Sponsor will review safety, tolerability, and efficacy (as needed) data of this study at regular intervals.

Eligibility criteria: Key Inclusion Criteria:

* Completion of any prior AOC 1001 studies with satisfactory completion of dosing and follow-up assessments and satisfactory compliance with the protocol requirements of the parent study, as determined by the Investigator.

Key Exclusion Criteria:

* Breastfeeding, pregnancy, or intent to become pregnant during the study.
* Unwilling to comply with contraceptive requirements.
* Any new conditions or worsening of existing condition that in the opinion of the Investigator would make the participant unsuitable for the study.

Primary outcomes:
measure: TEAEs
timeFrame: From enrollment to the end of treatment at 4 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04075669: Multiplex Strip Polymerase Chain Reaction for Diagnosis of Eye Infection Diseases From Corneal Scraping Samples
Official title: Multiplex Strip PCR for Valid, Fast and Comprehensive Multi-pathogen Detection to Support the Diagnosis of Eye Infection Diseases (Endophthalmitis, Keratitis, Corneal Ulcers) From Corneal Scraping Samples
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Endophthalmitis
Keratitis
Corneal Ulcer
Eye Infections
Keywords: Multiplex solid-phase strip PCR
Eye Infections
Endophthalmitis
Corneal Ulcer
Keratitis
Corneal Scraping Samples
Lead sponsor: Fakultas Kedokteran Universitas Indonesia
Sponsor class: OTHER
First posted: 2019-09-03
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with eye infections (Keratitis, endophthalmitis, and corneal ulcer) in RSCM Kirana Infection and Immunology Division that registered since July 2019

Brief summary: The aim of this study is to see if multiplex strip PCR will detect the pathogen that causing eye infection from the corneal scraping samples with higher sensitivity and specificity than the current gold standard.


Eligibility criteria: Inclusion Criteria:

* Registered as new patients since July 2019 in RSCM Kirana
* Age more than 18 years
* Have an eye infection (keratitis, endophthalmitis and corneal ulcer) which required corneal scrapping sampling for further diagnosis

Exclusion Criteria:

- Not willing to become the participants by not filling the informed consent

Primary outcomes:
measure: Higher sensitivity and specificity by multiplex strip PCR than current gold standard
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jakarta Pusat
country: Indonesia
facility: RSUPN dr. Cipto Mangunkusumo (Cipto Mangunkusumo Hospital)
state: DKI Jakarta
Study officials:
affiliation: Infection and Immunology Department of Ophthalmology Faculty of Medicine Universitas Indonesia
name: Dr. dr. Made Susiyanti, Sp.M(K)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05926869: Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris
Official title: Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acne Vulgaris
Lead sponsor: Jinnah Postgraduate Medical Centre
Sponsor class: OTHER_GOV
First posted: 2023-07-03
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acne vulgaris (AV) is a disease of the pilosebaceous unit that causes noninflammatory lesions (open and closed comedones), inflammatory lesions (papules, pustules, and nodules), and varying degrees of scarring. The key pathogenic processes includes alteration of follicular keratinization that leads to comedones; increased and altered sebum production under androgen control; follicular colonization by Propionibacterium acnes; . The role of topical antibiotics in treating acne is well established. Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. The extensive use of antibiotics in acne has lead to the development of resistance to antimicrobial therapy. Dapsone is known to have antibacterial as well as anti-inflammatory action which may help in reduction of acne.

Detailed description: Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris.

Eligibility criteria: Inclusion Criteria:

* moderate acne vulgaris
* either gender
* 20 to 50 yrs

Exclusion Criteria:

* systemic treatment taken
* pregnant or lactating women
* hematological abnormalities

Primary outcomes:
measure: Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris
timeFrame: It will be assessed upto 03 months
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: JPMC
state: Sindh
Study officials:
affiliation: Jpmc
name: khadija Asadullah, FCPS
role: PRINCIPAL_INVESTIGATOR
affiliation: Jpmc
name: Faiza Inam, FCPS
role: PRINCIPAL_INVESTIGATOR
affiliation: JPMC
name: Nazia Jabeen, FCPS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01309269: Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine
Official title: Non-interventional Study to Investigate the Long Term Effects of MIRCERA in Clinical Routine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anemia
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2011-03-07
Enrollment: 1083
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Chronic kidney disease patients treated with Mircera for renal anemia

Brief summary: This observational study will assess the effect of long-term treatment with Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients with renal anemia. Data will be collected from each patient for at least 24 months.


Eligibility criteria: Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Patients with chronic kidney disease (CKD), stages IV and V
* Treatment with Mircera according to label

Exclusion Criteria:

* Pregnant or breastfeeding women

Primary outcomes:
measure: Hemoglobin Levels at Monthly Intervals
timeFrame: Prior to Day 1, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24
measure: Percentage of Participants Within Pre-defined Range of Hemoglobin Values
timeFrame: Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24
measure: Average Methoxy Polyethylene Glycol-epoetin Beta Dose
timeFrame: Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24
Secondary outcomes:
Other outcomes:
Locations:
city: Lüdenscheid
country: Germany
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References: